I Cell Disease News and Research

RSS

Mast Therapeutics' data show that MST-188 reduces aggregation of both older and younger RBC

Mast Therapeutics, Inc. today announced that two posters for its lead product candidate, MST-188, were presented at the 7th Annual Sickle Cell Disease Research & Educational Symposium, currently underway in Miami.

18 Apr 2013

UI Health to launch EPIC program to cut frequent ER visits, readmissions to hospital

The University of Illinois Hospital & Health Sciences System is taking steps to reduce frequent emergency room visits and readmissions to the hospital.

17 Apr 2013

GlycoMimetics reports Phase 2 clinical study results of GMI-1070

GlycoMimetics, Inc. today announced top line clinical results from a Phase 2 study of GMI-1070 in patients experiencing vaso-occlusive crisis of sickle cell disease.

17 Apr 2013

VCU researchers shed light on biopsychosocial, spiritual effects of taking opioids for noncancer pain

Researchers from Virginia Commonwealth University sought to shed light on the biopsychosocial and spiritual effects of taking prescribed opioids to treat noncancer pain.

15 Apr 2013

Chemotherapy-free stem cell transplant shows promise for sickle cell disease

Two brothers have been cured of their sickle cell disease at the University of Illinois Hospital & Health Sciences System using a relatively uncommon type of stem cell transplant that is performed without chemotherapy.

6 Mar 2013

AAP, ACMG release guidelines on best practices for genetic testing and screening of children

For the first time, the American Academy of Pediatrics (AAP) and the American College of Medical Genetics and Genomics (ACMG) spoke with one voice and released a set of recommendations and guidelines on best practices for genetic testing and screening of children.

5 Mar 2013

Tranylcypromine may also hold promise in treating sickle cell disease

An antidepressant drug used since the 1960s may also hold promise for treating sickle cell disease, according to a surprising new finding made in mice and human red blood cells by a team from the University of Michigan Medical School.

19 Feb 2013

Gamida Cell announces results from NiCord Phase I/II study on hematological malignancies

Gamida Cell announced today the successful results of the Phase I/II study of its second pipeline product NiCord, umbilical cord derived stem cells expanded using the company's proprietary NAM technology.

15 Feb 2013

TAPS supports preoperative transfusion

Preoperative transfusion may protect sickle cell patients from surgical complications, suggest findings published in The Lancet.

29 Jan 2013

Clinical trial to evaluate cyclodextrin against Niemann-Pick disease type C1

A clinical trial to evaluate a drug candidate called cyclodextrin as a possible treatment for Niemann-Pick disease type C1 (NPC), a rare and fatal genetic disease, will start today, researchers announced.

24 Jan 2013

Penn Medicine to establish new center for treatment and research of blood diseases

Penn Medicine will establish the Philadelphia region's first dedicated center for the treatment and research of blood diseases by combining the expertise of physicians who specialize in the care of blood disorder patients of all ages along with basic science and clinical researchers who are working to advance treatments for these illnesses.

18 Jan 2013

Enrollment complete in GlycoMimetics’ GMI-1070 Phase 2 study for sickle cell disease

GlycoMimetics, Inc. (GMI), a clinical-stage biotechnology company researching a new class of glycobiology-based therapies for a broad range of diseases, today announced that it has completed enrolling patients in its Phase 2 study of GMI-1070, its lead investigational drug candidate.

18 Jan 2013

Research unveils key gaps in continuity of care for sickle cell patients

Research unveiling key gaps in continuity of care for sickle cell patients transitioning from pediatric to adult care will be presented this week during the 54th Annual Meeting of the American Society of Hematology (ASH).

11 Dec 2012

Acetylon announces results from selective HDAC 1/2 inhibitor preclinical study on SCD and bT

Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced results from a preclinical study of a selective histone deacetylase (HDAC) 1/2 inhibitor for the treatment of sickle cell disease (SCD) and beta-thalassemia (bT) at the 54th Annual Meeting of the American Society of Hematology (ASH), taking place in Atlanta, Georgia.

11 Dec 2012

Patients with sickle cell disease rely more on emergency room

Patients with sickle cell disease rely more on the emergency room as they move from pediatric to adult health care, according to researchers at Washington University School of Medicine in St. Louis.

10 Dec 2012

Sickle cell disease trial completes phase 3 patient enrollment

Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine company, today announced the completion of patient enrollment for its phase 3 clinical trial to study L-glutamine as a treatment for sickle cell disease.

5 Dec 2012

ADVENTRX Pharmaceuticals updates corporate website

ADVENTRX Pharmaceuticals, Inc. today announced the launch of its redesigned and updated corporate website,www.adventrx.com. The new website features clinician videos, patient resources, and important news pertaining to sickle cell disease and ADVENTRX's lead product candidate, ANX-188 (purified poloxamer 188).

3 Dec 2012

CINJ experts available to comment on importance and uses of blood donations

Every two seconds, someone in the United States is in need of blood. According to the American Red Cross, more than 44,000 blood donations are needed each day. With just one donation of a pint of blood, up to three lives can be saved. Nationally, less than 38 percent of the population is eligible to give blood. In New Jersey, according to the state Department of Health fewer than four percent of eligible residents donate regularly, resulting in the critical need for blood donations.

30 Nov 2012

Acetylon's ective histone deacetylase inhibitors to be showcased at 54th ASH annual meeting

Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced that its selective histone deacetylase (HDAC) inhibitors will be featured in five posters and one oral presentation at the 54th Annual Meeting of the American Society of Hematology (ASH), taking place December 8-11, 2012, in Atlanta, Georgia.

21 Nov 2012

Sickle cell disease treatments: An interview with Dr Niihara, CEO of Emmaus Medical

Sickle cell disease is a devastating hereditary condition that affects millions of people, particularly those in West and Central Africa as well as people of African descent in the United States, Europe and South America.

23 Oct 2012